Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811918 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL30307671 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL15684270 | 1.00 | BRD4 (0.63) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL3826960 | 0.89 | BRD4 (0.53) | BRD4MAPTPOLBRECQLGAA | |
| Glycerin SCHEMBL3843494 | 0.86 | MAPT (0.51) | BRD4MAPTPOLBRECQLGAA | |
| Triethylene Glycol SCHEMBL1362131 | 0.83 | BRD4 (0.51) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL14372529 | 0.83 | BRD4 (0.63) | BRD4MAPTPOLBRECQLSMN1; SMN2 | |
| SCHEMBL13803892 | 0.83 | BRD4 (0.63) | BRD4MAPTPOLBRECQLSMN1; SMN2 | |
| Itaconate SCHEMBL2524622 | 0.82 | BRD4 (0.50) | BRD4MAPTPOLBRECQLGAA | |
| SCHEMBL29138381 | 0.82 | BRD4 (0.46) | BRD4MAPTPOLBRECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020118091-A1 | ONDANSETRON IN-ADHESIVE TRANSDERMAL PATCH | STARTON THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | claimed |
| EP-3193849-A1 | OPIPRAMOL PATCH | Neuroderm, Ltd. (IL) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042413-A1 | OPIPRAMOL PATCH | NEURODERM, LTD. (IL) | 2016-03-24 | — | — | WO | claimed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| US-7879344-B2 | contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-02-01 | — | — | US | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| EP-2040693-A2 | TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION | Kimberly-Clark Worldwide, Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| US-7137975-B2 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-20020161323-A1 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT INC. | 2002-10-31 | — | — | US | claimed |
| EP-0813879-B1 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | claimed |
| EP-0475963-A4 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | — | 1992-06-24 | — | — | EP | claimed |
| EP-0471683-A4 | BIS-(PYRROLIDONYL ALKYLENE) BIGUANIDES | — | 1992-04-22 | — | — | EP | claimed |
| EP-0475963-A1 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | ISP INVESTMENTS INC. (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0471683-A1 | BIS-(PYRROLIDONYL ALKYLENE) BIGUANIDES | GAF CHEMICALS CORPORATION (US) | 1992-02-26 | — | — | EP | claimed |
| WO-1990013544-A1 | POLYMERIZABLE PYRROLIDONYL OXAZOLINE MONOMERS, HOMOPOLYMERS AND COPOLYMERS | GAF CHEMICALS CORPORATION (US) | 1990-11-15 | — | — | WO | claimed |
| WO-1990013536-A1 | BIS-(PYRROLIDONYL ALKYLENE) BIGUANIDES | GAF CHEMICALS CORPORATION (US) | 1990-11-15 | — | — | WO | claimed |
| US-4952704-A | WATER SOLUBLE MICROBIOCIDES; NONTOXIC, COMPATIBLE WITH SURFACTANTS | GAF CHEMICALS CORPORATION (US) | 1990-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | BRD4 121/4885MAPT 2590/4885POLB 244/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | BRD4 804/4885MAPT 1463/4885POLB 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.